Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

por Hurvitz, Sara A., Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A., Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A., Symmans, W. Fraser, Thompson, Alastair M., Slamon, Dennis
Publicado 2019

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer...

por Slamon, Dennis J., Fasching, Peter A., Hurvitz, Sara, Chia, Stephen, Crown, John, Martín, Miguel, Barrios, Carlos H., Bardia, Aditya, Im, Seock-Ah, Yardley, Denise A., Untch, Michael, Huang, Chiun-Sheng, Stroyakovskiy, Daniil, Xu, Binghe, Moroose, Rebecca L., Loi, Sherene, Visco, Frances, Bee-Munteanu, Valerie, Afenjar, Karen, Fresco, Rodrigo, Taran, Tetiana, Chakravartty, Arunava, Zarate, Juan Pablo, Lteif, Agnes, Hortobagyi, Gabriel N.
Publicado 2023